Dr. Cytryn is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 E 53rd St
New York, NY 10022Phone+1 212-639-2000
Education & Training
- NYU Grossman School of MedicineResidency, Internal Medicine, 2017 - 2020
- Icahn School of Medicine at Mount SinaiClass of 2017
Certifications & Licensure
- NY State Medical License 2019 - 2026
- NJ State Medical License 2024 - 2025
- CT State Medical License 2024 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer Start of enrollment: 2024 Feb 01
Roles: Contact
Publications & Presentations
PubMed
- 1 citationsPD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays.Samuel J Klempner, Eric S Cowden, Samuel L Cytryn, Matteo Fassan, Hisato Kawakami
JCO Precision Oncology. 2024-06-01 - 2 citationsHER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers.Samuel L Cytryn, Yelena Y Janjigian
Journal of the National Comprehensive Cancer Network. 2023-04-01 - 21 citationsHaploidentical Hematopoietic Stem Cell Transplantation Followed by 'Post-Cyclophosphamide': The Future of Allogeneic Stem Cell Transplant.Samuel Cytryn, Maher Abdul-Hay
Clinical Hematology International. 2020-04-19
Press Mentions
- Bispecific Antibodies in Gastric Cancer: Big Questions but Bigger Potential?August 26th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: